“…the development of Omnipaque set the gold standard for non-ionic imaging agents”3
Used since 1982 in everyday examinations or pioneering procedure, Omnipaque has been used extensively in over 100 countries, more than over 690 million procedures,2 examined in over 40 doctoral theses and 6,500 clinical studies, and subject to large safety surveillance studies on different continents.
The quality you want from contrast enhancement
- Omnipaque has been unsurpassed by any low-osmolar contrast media (LOCM) for either diagnostic efficacy or tolerability at equi-attenuating doses in head-to-head trials4-18
|
Examples of clinical comparisons of other LOCM with Omnipaque
|
| Comparator |
Procedure |
Superior efficacy to
Omnipaque at equi-
attenuating doses* |
| iopamidol |
myelography (n=363)4
paediatric cardiac angiography (n=62)5
|
NO
NO |
| iomeprol |
intravenous urography (n=60)6
myelography (n=83)7
|
NO
NO |
| iopromide |
aortography + visceral angiography (n=125)8
excretory urography (n=200)9
|
NO
NO |
| iobitridol |
CT of the head (n=276)10
hepatic CT (n=146)11
|
NO
NO |
| ioversol |
intravenous urography (n=80)12
peripheral + visceral arteriography (n=60)13
|
NO
NO |
| ioxaglate |
lower limb phlebography (n=120)14
angiography (n=80)15
|
NO
NO |
*e.g. opacification, image quality, ability to make a diagnosis
A range of concentrations, volumes and pack sizes for optimal usage**
- 140, 240, 300 and 350 mgI/mL19
- 10, 20, 40, 50, 100, 200 and 500 mL19
**Concentrations, volumes and packaging vary from country to country
References:
1. WHO Model List of Essential Medicines, 19th list, April 2015.
Available at: https://www.who.int/medicines/publications/essentialmedicines/en/.
Accessed on 17 October 2019.
2. Data on File, GE Healthcare, 2019.
3. Widmark JM. Proc (Bayl Univ Med Cent) 2007; 20: 408-17.
4. Lamb JT. Invest Radiol 1985; 20(Suppl.) S37–S43.
5. Rubin CME et al. Brit J Radiol 1987; 60: 133–5.
6. Harding JR et al. Brit J Radiol 1995; 68: 712–5.
7. Katayama H et al. Invest Radiol 2001; 36: 22–32.
8. Faykus MH et al. Invest Radiol 1994; 29 (Suppl.1): S98–S101.
9. Bischoff W. Fortschr Röntgenstr 1989; 128: 108–10.
10. Drouillard J et al. Acta Radiol 1996; 37 (Suppl.400): 56–61.
11. Legmann P et al. Eur Radiol 2001; 11: 2220–7.
12. Kaufman AJ et al. Urol Radiol 1990; 12: 56–60.
13. Cutcliff WB et al. Invest Radiol 1989; 24 (Suppl.1): S56–9.
14. Bertrand P et al. Acad Radiol 1995; 2: 683–6.
15. Krouwels MM et al. Eur J Radiol 1996; 22: 133–5.
16. Gomi T et al. Eur Radiol 2010; 20: 1631–5.
17. LaBounty TM et al. Am J Cardiol 2012; 109: 1594–9.
18. Dillman JR et al. Am J Roentgenol 2012; 198: 392–7.
19. Omnipaque Summary of Product Characteristics, 2019. JB7787/JB71466SE 10-2019
